Introduction: Atezolizumab plus bevacizumab (ATZ+BV) treatment has become the first-line regimen for unresectable hepatocellular carcinoma (u-HCC). Prediction of response to it might be clinically beneficial. Using peripheral blood parameters, we aimed to construct a prediction model for ATZ...
The remaining cells were stained with a mixture of HLA-A*0201/peptide dextramers and pentamer (Immudex and Proimmune, Supplementary Table 4) for 10 min at room temperature followed by anti-CD3-BV510 (UCHTI, Biolegend), anti-CD8-A700 (RPA-T8, BD), anti-CD4-PE-Cy7 (RPA-T4, e...
HEPATOCELLULAR-CARCINOMAAtezolizumab plus bevacizumab (Atez/BV) as first-line therapy and lenvatinib (LEN) as second-line therapy are the recommended ... M Kimura,S Yamada,M Go,... - 《Oncology Letters》 被引量: 0发表: 2024年 Pretreatment eosinophil count predicts response to atezolizumab plus...
Publisher: Elsevier BV Read this article at ScienceOpenPublisherPubMed Review Bookmark Cite as... There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience. ...
(Immudex and Proimmune,Supplementary Table 4) for 10 min at room temperature followed by anti-CD3-BV510 (UCHTI, Biolegend), anti-CD8-A700 (RPA-T8, BD), anti-CD4-PE-Cy7 (RPA-T4, eBioscience), anti-CD45RA-eVolve605 (HI100, eBioscience), anti-CCR7-BV421 (G043H7, Biolegend),...
Wheeler DC, Toto RD, Stefánsson BV, et al. A pre-specified analysis of the DAPA-CKD trial demonstrates the effects of dapagliflozin on major adverse kidney events in patients with IgA nephropathy. Kidney International. 2021;100(1):215–224. doi:10.1016/j.kint.2021.03.033 26. Mei J, Tang...
doi:10.1093/annonc/mdy424.037B.I. RiniM. HuseniM.B. AtkinsD.F. McDermottT.B. PowlesB. EscudierR. BanchereauL.-F. LiuN. LengJ. FanElsevier BVAnnals of Oncology
The patient was admitted with hematemesis 114days after ATZ/BV administration. During EGD, the EVs deteriorated to F3 grade, although hemostasis had already been achieved. The evaluation was discontinued during the observation stage because of the worsening hepatic reserve.#Neither patient had EVs ...
PD-L1 is expressed on myeloma cells and appears to be upregulated in patients (pts) with relapsed or refractory (R/R) multiple myeloma (MM). Daratumumab (dara) is an anti-CD38 mAb approved for the tx of R/R MM; tx options are limited for pts who progress on dara. Given the anti-...
Organ preservation is increasingly being pursued in patients with a clinical complete response (cCR) following neoadjuvant treatment, thereby aiming to avoid TME-surgery. Based on preclinical data suggesting immunomodulatory effects of RT, and the synergy of combined PD-L1/VEGF blockade in several ...